WALTHAM, Mass.--(BUSINESS WIRE)--Corindus, a Siemens Healthineers Company and leading developer of precision vascular robotics, announced today that Circulation: Cardiovascular Interventions has published clinical results from a comparative study between robotic percutaneous coronary intervention (PCI) and manual PCI. Findings from the study show robotic PCI with the CorPath GRX System reduces patient exposure to radiation by 20% compared to manual PCI with no increase in fluoroscopy time or contrast utilization.
The paper, titled Comparison of Robotic Percutaneous Coronary Intervention with Traditional Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis of a Large Cohort, discusses the study of 996 consecutive patients, of which 310 underwent robotic PCI and 686 underwent manual PCI. The study sought to measure air kerma (AK), dose area product (DAP), fluoroscopy time, volume of contrast and total procedural time.
“These findings further represent the benefits of robotic-assisted intervention, particularly for patients,” stated Dr. Tejas Patel, Chairman and Chief Interventional Cardiologist of the Apex Heart Institute in Ahmedabad, Gujarat, India, and the lead investigator of the study. “The application of vascular robotics has shown other benefits through added precise device manipulation, and now, creates a safer environment for patients. I am honored to share my experience with the clinical community and to offer the benefits of this technology to my patients.”
Interventional cardiologists experience the highest amount of radiation exposure of any medical professionals from fluoroscopy systems used in cardiovascular procedures, which can dramatically increase their risk for cancer, cataracts, and other radiation-related illnesses. The CorPath GRX design protects physicians by removing them from the radiation field, and has been shown to reduce radiation exposure by over 95%. Dr. Patel’s study data proves robotic intervention also provides significant health benefits to patients by limiting radiation exposure as compared to a manual procedure.
“The power of robotic intervention lies in its ability to increase patient and physician safety and improve clinical outcomes for delicate cardiovascular procedures,” said Mark Toland, CEO of Corindus. “Dr. Patel’s study validated our core beliefs and demonstrated a notable clinical benefit for patients undergoing robotic procedures. We see tremendous potential in health care to continue to make treatment paradigms safer and more effective through robotics and look forward to playing a significant role in that evolution.”
To download and read the full publication, please visit Circulation: Cardiovascular Interventions.
Corindus will be hosting a live webinar with Dr. Tejas Patel discussing the study findings, followed by a Q&A session on May 28, 2020 at 7:00am EDT. Please click here to register for the webinar.
To learn more about Corindus and CorPath GRX, please visit www.corindus.com.
About Corindus
Corindus, a Siemens Healthineers Company, is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com, and follow @CorindusInc.
